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Abstract: 
Introduction: Li-Fraumeni Syndrome (LFS) is a rare, autosomal dominant disease that is typically screenedfor 
and identified in patients with a known history of cancer and family history ofcancer. 
Presentation of Case: Ms. DA is an adopted 39-year-old South American female with a past medical history of 
iron deficiency anemia, celiac disease, and polio. She presented with ductal carcinoma in-situ with spindle cell 
atypia at age 35 and leiomyosarcoma of the ankle at age 36. Genetic counseling was offered due to her age and 
cancer types, with subsequent genetic testing revealing a TP53-R337H mutation, which was diagnostic of LFS. 
Given her high risk status, extensive cancer screenings at common LFS body sites were recommended, but she 
was lost to follow-up. Four years later, she returned after discovering a new right breast mass on self-examination. 
She was referred to a new breast surgeon, who was able to establish consistent and close follow-up while 
providing counseling and education regarding lifetime risk and cancer trajectory of classical LFS compared to the 
Brazilian LFS-subtype. 
Conclusion: The importance of having a high level of suspicion for patients with anunknown family history is 
crucial as seen in this case. Without a biological familyhistory, clinicians rely on their judgement to decide when 
further work-up is warranted.Advancements in medicine and genetic testing have increased the ability to 
accuratelydiagnose genetic diseases to help patients make life-saving decisions about theirhealth.  
 
  
 
Chen JH et al. American Journal of Cancer Case Reports        2019, 7:40-44                                                                  Page 2 of  5 
Ivy Union Publishing | http: //www.ivyunion.org                                                                             October 18, 2019 | Volume 7, Issue 1
  
 
Introduction 
Li-Fraumeni Syndrome (LFS) is an inherited autosomal dominant malignancy that is characterized by 
the development of multi-system cancers due to a deficiency in the cell cycle regulator, TP53 (Figure 
1)[1]. Also known as Sarcoma-Breast-Leukemia-Adrenal Gland (SBLA) Cancer Syndrome, 
approximately 400 families in the Unites States have been described in literature with this disease 
since its initial characterization in 1969 [1, 2].  The overall prevalence worldwide is less known, with 
an estimate of over 1000 multigenerational families across 172 countries. Family history plays a 
significant role in risk stratification and screening protocols since definitive diagnosis requires 
physicians to identify the risk and order DNA sequencing to identify TP53 mutations or deletions [3].  
In presence of young age and absence of family history, providers need to have an even higher index 
of suspicion in caring for patients with possible multi-system cancers. Here we present an adopted 
patient with no known biological family history with a classical LFS presentation.  
 
 
 
 
Figure 1 LFS and its common cancer associations 
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Case presentation 
 Ms. DA is a 39-year-old South American female with a past medical history of iron 
deficiency anemia, celiac disease, and polio. She was adopted as a child from Brazil and was unaware 
of her biological family’s medical history. She initially presented at age 35 for an early screening 
mammogram, which showed a well-circumscribed density in the central right breast. An image-guided 
core biopsyrevealed ductal carcinoma in-situ with spindle cell atypia, with subsequent right breast 
lumpectomy and whole breast radiation treatment. One year later, she returned with a new left ankle 
mass. Excisional biopsy and resection revealed a leiomyosarcoma with clear margins noted, with 
radiotherapy afterwards.  
 Genetic counseling was offered due to her age and cancer types, with subsequent genetic 
testing revealing a TP53-R337H mutation, which was diagnostic of LFS. Given her high risk status, 
extensive cancer screeningsat common LFS body sites were recommended, but she was lost to follow-
up.  
 Four years later, she returned after discovering a new right breast mass on self-examination. 
Mammogram and ultrasound confirmed a benign hematoma, likely due to trauma. She was referred to 
a new breast surgeon, who was able to establish consistent and close follow-up while providing 
counseling and education regarding lifetime risk and cancer trajectory of classical LFS compared to 
the Brazilian LFS-subtype. After extensive discussion, the patient opted for prophylactic bilateral 
mastectomy and reconstruction due to concerns of prior radiotherapy exposure to her breast. Since 
then, she had no new complaints and is compliant with standard LFS cancer screening schedules.  
Discussion 
 LFS carries a primary cancer risk of up to 100%, by the age of 60 in women, and a risk of up 
to 73% in men [4]. Furthermore, these patients have a high risk of developing a secondary and a 
tertiary malignancy of about 30-57% and 38%, respectively [5, 6]. Early detection and referral for 
genetic screening becomes complicated in situations such as Ms. DA as LFS screening criteria 
consistently utilize family history as a defining feature (Figure 2)[7].  Other protocols with and 
without family history have also been used, with varying success rates [8-11]. Despite having an 
unknown family history and only fulfilling the personal history of cancer criteria, her presentation 
relative to her age triggered a high index of clinical suspicion and warranted further work-up. 
 
 
Figure 2 Various criteria for assessing need for genetic testing in definitive diagnosis of LFS. 
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 Subsequent cancer screenings with individuals with LFS include: annual physical, clinical, 
self-breast, and dermatological examinations, whole body MRI screening for secondary cancers, 
colorectal screening and risk-reducing bilateral mastectomy [12, 13]. High recurrences of secondary 
and tertiary cancers rates in LFS require patients to undergo strict surveillance studies. Of note, 
compared to the high lifetime primary cancer risk of most individuals/families with LFS, the Brazilian 
population’s specific R337H founder mutation has only a 60% lifetime risk with improved survival 
rates post-treatment[14].  
 The differential diagnosis for LFS can include BRCA1/BRCA2 mutations for breast 
cancer, and the family of DNA repair enzymes of MLH1, MSH2, MSH6, PMS1, and PMS2 in 
mismatch repair cancer (Lynch) syndrome[12, 13]. Advances in genetic screening and testing, 
however, has eliminated the uncertainty of these inherited cancer syndromes through accurate 
diagnosis. Despite its rarity and lack of supporting family history, Ms. DA was able to make 
potentially lifesaving decisions due to the clinical judgement of her physicians. Further studies are 
required to assess the utility of genetic testing in adoption cases where family history is unavailable. 
Conclusion 
Li Fraumeni Syndrome is a rare, autosomal dominant disease that is typically screened for and 
identified in patients with a known history of cancer and family history of cancer. As seen in this case, 
the importance of suspicion and clinical judgementfor patients with an unknown family history is 
crucial. In the setting of global migration, physicians need to have high clinical suspicion when 
confronted with abnormal age to cancer presentations Advancements in medicine and testing have 
increased our ability to accurately diagnose genetic diseases to help patients make life-saving 
decisions about their health and healthcare. 
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